Gan & Lee Pharmaceuticals Co Ltd (603087) — Cash Flow Quality Index

Latest as of September 2025: 1.20x

Gan & Lee Pharmaceuticals Co Ltd (603087) has a Cash Flow Quality Index of 1.20x as of September 2025. Operating cash flow of CN¥257.27 Million exceeds net income of CN¥214.66 Million, indicating high earnings quality where cash backs reported profits. Also explore Gan & Lee Pharmaceuticals Co Ltd asset portfolio for the complete picture of this company's asset base.

Cash Flow Quality Index

1.20x
Operating CF / Net Income

Operating Cash Flow

CN¥257.27 Million
CNY

Net Income

CN¥214.66 Million
CNY

Data as of

Sep 2025
Most recent filing

Gan & Lee Pharmaceuticals Co Ltd Cash Flow Quality Index (2013–2025)

Historical Cash Flow Quality Index for Gan & Lee Pharmaceuticals Co Ltd across 12 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Gan & Lee Pharmaceuticals Co Ltd tangible equity quality to evaluate the tangible quality of the company's equity base.

Annual Cash Flow Quality Index for Gan & Lee Pharmaceuticals Co Ltd (2013–2025)

Year-by-year earnings quality comparison for Gan & Lee Pharmaceuticals Co Ltd. For live market cap and the full company financial profile, see 603087 market cap overview.

Year Quality Index Operating CF (CNY) Net Income YoY Change
2025 0.69x CN¥784.28 Million CN¥1.14 Billion ▼ -21.5%
2024 0.87x CN¥537.31 Million CN¥614.66 Million ▼ -30.5%
2023 1.26x CN¥427.69 Million CN¥340.07 Million ▲ +69.5%
2021 0.74x CN¥1.08 Billion CN¥1.45 Billion ▼ -26.4%
2020 1.01x CN¥1.24 Billion CN¥1.23 Billion ▲ +2.0%
2019 0.99x CN¥1.15 Billion CN¥1.17 Billion ▲ +120.9%
2018 0.45x CN¥418.04 Million CN¥933.97 Million ▼ -49.1%
2017 0.88x CN¥949.60 Million CN¥1.08 Billion ▼ -12.1%
2016 1.00x CN¥769.63 Million CN¥769.63 Million ▲ +0.0%
2015 1.00x CN¥447.42 Million CN¥447.42 Million ▲ +0.0%
2014 1.00x CN¥305.22 Million CN¥305.22 Million ▲ +0.0%
2013 1.00x CN¥204.73 Million CN¥204.73 Million
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.